Kirchgraber Paul R 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Feb 7, 2023
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2023-02-04+560→ 13,892 total - Tax Payment
Common Stock
2023-02-06$244.50/sh−164$40,098→ 13,728 total - Exercise/Conversion
Restricted Stock Unit
2023-02-04−560→ 1,894 total→ Common Stock (560 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested.
- [F4]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.